DermTech, Inc. DMTKQ
0.00
0.00
NaN
as of 13 Aug
- Market cap
- $3.3M
- P/E
- 0.0×
Follow DMTKQ
Growth Flags
show if company had growth for consecutive years
| Mar '24 | Dec '23 | Sep '23 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.53 | 3.54 | 3.46 | 5.89 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.40) | (4.26) | (2.61) | (3.56) | |
P/B ratio |
0.60 | 0.95 | 0.68 | 0.94 | |
Price to Tangible BV |
0.60 | 0.95 | 0.68 | 0.94 | |
EV/Sales |
(0.96) | (0.11) | (1.28) | (0.25) | |
EV/EBITDA |
0.17 | 0.02 | 0.17 | 0.03 | |
EV/Operating CF |
0.21 | 0.02 | 0.22 | 0.04 | |
EV/FCF |
0.21 | 0.02 | 0.21 | 0.04 | |
Quick Ratio |
3.31 | 4.35 | 5.68 | 5.62 | |
Current Ratio |
3.53 | 4.59 | 6.01 | 5.85 | |
Net Debt/EBITDA |
2.03 | 3.00 | 3.66 | 2.79 | |
Debt/Assets |
0.03% | 0.03% | 0.03% | 0.03% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.11 | 0.09 | 0.09 | 0.08 | |
Operating CF/Net income |
0.86 | 0.67 | 0.99 | 0.74 | |
Capex/Depreciation |
0.00 | 0.14 | (0.04) | (0.20) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
84.94% | 85.32% | 91.83% | 97.66% | |
Selling, General and Administrative Expense of Revenue |
466.97% | 429.26% | 418.57% | 709.87% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
70.14% | 80.30% | 80.79% | 188.82% | |
Graham Net Nets |
(0.78) | (0.06) | 0.22 | 0.30 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(391.30%) | (189.16%) | (238.78%) | (150.00%) | |
Free Cash Flow Yield |
(304.72%) | (143.73%) | (177.93%) | (113.99%) | |
Revenue per Share |
0.11 | 0.12 | 0.12 | 0.13 | |
Operating CF per Share |
(0.49) | (0.39) | (0.56) | (0.73) | |
Capex per Share |
0.00 | 0.01 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.49) | (0.38) | (0.56) | (0.74) | |
Cash per Share |
1.12 | 1.71 | 2.02 | 2.71 | |
Shareholders Equity per Share |
1.15 | 1.75 | 2.16 | 2.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.15 | 1.75 | 2.16 | 2.77 | |
Free Cash Flow |
(17.12) | (12.54) | (19.09) | (23.46) | |
Working Capital |
31.68 | 48.31 | 63.29 | 77.73 | |
Capital Expenditures |
— | 0.16 | (0.05) | (0.26) | |
Net Current Asset Value |
(18.78) | (3.00) | 11.10 | 24.75 | |
EV/EBIT |
0.16 | 0.02 | 0.16 | 0.03 | |
Capex to Sales |
0.00 | (0.04) | 0.01 | 0.07 | |
Net Profit Margin |
(520.42%) | (486.52%) | (489.50%) | (788.02%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.09 | 3.38 | 4.85 | 4.91 | |
Average Payables |
1.80 | 1.95 | 2.35 | 1.59 | |
Average Inventory |
1.20 | 1.38 | 1.29 | 1.39 | |
Average Assets |
140.05 | 162.00 | 165.98 | 186.59 | |
Average Common Equity |
73.62 | 94.76 | 114.03 | 133.33 |
Columns are period end dates